• EN/ES

    Orthopedics

    WebHealthNetwork : 2,378,479


  • Benefits & Savings

  • : Attention Deficit Disorder with Hyperactivity

Attention Deficit Disorder with Hyperactivity - 737 Studies Found

Completed : Safety, Tolerability, Pharmacokinetic, and Efficacy Study of SPD489 in Preschool Children With Attention-deficit/Hyperactivity Disorder
: Attention Deficit Hyperactivity Disorder (ADHD)
: 2015-03-19
: Drug: SPD489 All subjects will begin with 5mg of SPD489 daily and will be titrated until optimal dose is
Completed : Safety and Efficacy Study of SHP465 in Children and Adolescents Aged 6-17 Years With Attention-Deficit Hyperactivity Disorder (ADHD)
: Attention Deficit Hyperactivity Disorder (ADHD)
: 2015-06-03
:
  • Drug: SHP465 12.5mg and 25mg c

Completed : Efficacy and Safety of Lisdexamfetamine Dimesylate (LDX) in Adolescents With Attention-Deficit/Hyperactivity Disorder (ADHD)
: Attention Deficit Hyperactivity Disorder (ADHD)
: 2008-08-12
:
  • Drug: LDX 30 mg Eligible subje

Completed : Atomoxetine Versus Placebo for Symptoms of Attention-Deficit/Hyperactivity Disorder (ADHD) in Children and Adolescents With Autism Spectrum Disorder
:
  • Autistic Disorder
  • Attention Deficit Disorder With Hyperactivity
    : 2006-09-22
    :
    • Drug: Atomoxetine Other Names:

Active, not recruiting : A Study of Delayed and Extended Release Formulation of Dextroamphetamine Sulfate (HLD100) in Children With Attention-Deficit/Hyperactivity Disorder
: Attention-Deficit Hyperactivity Disorder (ADHD)
: 2016-07-28
: Drug: HLD100 Treatment Other Name: Dextroamphetamine
Recruiting : A Biofeedback Training in Schoolchildren With an Attention-Deficit/Hyperactivity Disorder (ADHD)
: Attention-deficit Hyperactivity Disorder of Childhood or Adolescence Nos
: 2015-10-07
:
  • Behavioral: EMG-based biofeedback training

Completed : Phase I Single Dose, Open-Label Pharmacokinetic Study and Single-Blind, Placebo-Controlled Dose Escalation Study of NFC-1 in Adolescents With Attention-Deficit Hyperactivity Disorder
: Attention-deficit Hyperactivity Disorder (ADHD)
: 2014-11-04
: Drug: NFC-1 Single-dose, open label administration to assess safety, tolerability, and pharmacokinetics
Completed : Treatment of Traumatic Brain Injury (TBI)-Related Attention Deficits in Children
:
  • Traumatic Brain Injury
  • Attention Deficit Disorder

: 2016-03-08
:
  • Drug: Lisdexamfetamine Lisdexa

Completed : Efficacy and Safety of Dex-Methylphenidate Extended Release 30 mg Versus 20 mg in Children (6-12 Years) With Attention-Deficit/Hyperactivity Disorder (ADHD) in a Laboratory Classroom Setting.
: Attention-Deficit/Hyperactivity Disorder (ADHD)
: 2008-10-16
:
  • Drug: Dex-Methylphenidate hydrochloride Extended Release (Focalin® XR)

Completed : Impact of Attention Deficit/Hyperactivity Disorder and Substance Use Disorder on Motorcycle Traffic Accidents
: Attention Deficit Hyperactivity Disorder
: 2007-09-26
:
  • Drug: Methylphenidate Methylph

<<< Previous | Next >>>
Orthopedics Health
Orthopedics Health WebHealth Network Media
  • WebHealthNetwork
  • DiabetesHealthMatters
  • HeartandStrokeHealth
  • WomensHealthCareCommunity
  • AsthmaHealthCenter
  • CancerHealthCenter
  • MentalHealthHelpCenter
  • Skincarehealthcenter
  • DigestiveTractHealth
  • VaccineHealthCenter
  • PainHealthCenter
  • FightingAddictionCenter
  • ObesityHealthMatters
  • SeniorHealthcareMatters
  • BrainAndNerveCenter
  • PediatricsHealthCenter
  • RareDiseasesHealthCenter
  • Wealth Mason
  • Home Owners Circle
  • EasyInsuranceFinder
  • EduJumpStart
  • SaleSpider
  • ScoopCafe
  • SaleSpiderMedia
  • Viewpoint.World
  • TravelerBooked
  • TechNewsBytes
  • Contact Us
  • Advertising Privacy Policy

This site uses cookies for analytics and advertising. No personal information is collected.

© Orthopedics Health .

We use cookies to enhance your experience, analyze anonymized traffic, and deliver personalized content and ads. No personal information is collected. By using our website, you consent to our use of cookies and agree to our data practices as described in our Privacy Policy. To Reject, please change your browser settings.